-
摘要: 铁超负荷性心肌病在临床中较常见且病死率高，是原发性血色病和继发性铁超负荷疾病的主要死亡原因之一。由于早期症状缺乏特异性，铁超负荷性心肌病常被忽视，以至后期治疗效果差。随着心脏磁共振等技术的应用和发展，以及心肌细胞摄取铁离子机制研究的深入，铁超负荷性心肌病的早期诊断及治疗取得满意的效果。现就铁超负荷性心肌病的目前认识和研究进展进行综述。Abstract: Iron overload cardiomyopathy, which is one of the most common causes of mortality in patients with primary hemochromatosis or other conditions associated with secondary iron overload, is commonly seen in clinical practice.Symptoms of iron overload cardiomyopathy may be varied in the early process and are usually overlooked, which leading to a bad outcome.With the development of cardiovascular magnetic resonance imaging and the deeper research of mechanisms of iron transport into the myocardial cell, early diagnosis and treatment have achieved satisfactory results.In this review, we summarize the current status and progress of iron overload cardiomyopathy.
-
-
[1] Gulati V, Harikrishnan P, Palaniswamy C, et al.Cardiac involvement in hemochromatosis[J].Cardiol Rev, 2014, 22(2):56-68.
[2] Kremastinos DT, Farmakis D.Iron overload cardiomyopathy in clinical practice[J].Circulation, 2011, 124(20):2253-2263.
[3] Wongjaikam S, Kumfu S, Chattipakorn SC, et al.Current and future treatment strategies for iron overload cardiomyopathy[J].Eur J Pharmacol, 2015, 765:86-93.
[4] Kremastinos DT, Farmakis D, Aessopos A, et al.Beta-thalassemia cardiomyopathy:history, present considerations, and future perspectives[J].Circ Heart Fail, 2010, 3(3):451-458.
[5] Gujja P, Rosing DR, Tripodi DJ, et al.Iron overload cardiomyopathy:better understanding of an increasing disorder[J].J Am Coll Cardiol, 2010, 56(13):1001-1012.
[6] Kumfu S, Chattipakorn SC, Chattipakorn N.T-type and L-type Calcium Channel Blockers for the Treatment of Cardiac Iron Overload:An Update[J].J Cardiovasc Pharmacol, 2017, 70(5):277-283.
[7] Wijarnpreecha K, Kumfu S, Chattipakorn SC, et al.Cardiomyopathy associated with iron overload:how does iron enter myocytes and what are the implications for pharmacological therapy?[J].Hemoglobin, 2015, 39(1):9-17.
[8] Eid R, Arab NT, Greenwood MT.Iron mediated toxicity and programmed cell death:A review and a re-examination of existing paradigms[J].Biochim Biophys Acta, 2017, 1864(2):399-430.
[9] Farmakis D, Triposkiadis F, Lekakis J, et al.Heart failure in haemoglobinopathies:pathophysiology, clinical phenotypes, and management[J].Eur J Heart Fail, 2017, 19(4):479-489.
[10] Schmitt B, Golub RM, Green R.Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level:systematic review for the American College of Physicians[J].Ann Intern Med, 2005, 143(7):522-536.
[11] He T.Cardiovascular magnetic resonance T2* for tissue iron assessment in the heart[J].Quant Imaging Med Surg, 2014, 4(5):407-412.
[12] Buja LM, Roberts WC.Iron in the heart.Etiology and clinical significance[J].Am J Med, 1971, 51(2):209-221.
[13] Brittenham GM.Iron-chelating therapy for transfusional iron overload[J].N Engl J Med, 2011, 364(2):146-156.
[14] Fernandes JL, Loggetto SR, Verissimo MP, et al.A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major[J].Blood, 2016, 128(12):1555-1561.
[15] Kumfu S, Chattipakorn SC, Fucharoen S, et al.Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice[J].Exp Physiol, 2016, 101(4):521-539.
[16] Kremastinos DT, Tsetsos GA, Tsiapras DP, et al.Heart failure in beta thalassemia:a 5-year follow-up study[J].Am J Med, 2001, 111(5):349-354.
-
计量
- 文章访问数: 60
- PDF下载数: 26
- 施引文献: 0
下载: